FGA ELISA Kit for Human(Homo sapiens) | EIAab.comFGA ELISA Kit for Human(Homo sapiens) | EIAab.com

Language:

[Sign in] [Register]

Search Protein-oriented Product center.

For antibodies, ELISA/CLIA, proteins... Product center

Tips

Index > Protein center > FGA(Gene name) > Human

Add your favorite

FGA (Gene name),

Fibrinogen alpha chain (Protein name ), FIBA_HUMAN from NCBI database.

top

Come back to page head.

|

General Annotation

|

Antigen Annotation

|

3D

|

Predicted Eptitope

|

Vaild Sequence

|

Related Databases

|

Citations (5)

|

Feedback

Gene name:

FGA;

Protein name:

Fibrinogen alpha chain;

Alternative:

Organism:

Human (Homo sapiens).

General Annotation

Sub Unit:

Heterohexamer; disulfide linked. Contains 2 sets of 3 non-identical chains (alpha, beta and gamma). The 2 heterotrimers are in head to head conformation with the N-termini in a small central domain.

Function:

Fibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation.

Subcellular Location:

Secreted

Protein Attributes:

Sequence length:

866

Sequence:

50:

MFSMRIVCLV | LSVVGTAWTA | DSGEGDFLAE | GGGVRGPRVV | ERHQSACKDS |

100:

DWPFCSDEDW | NYKCPSGCRM | KGLIDEVNQD | FTNRINKLKN | SLFEYQKNNK |

150:

DSHSLTTNIM | EILRGDFSSA | NNRDNTYNRV | SEDLRSRIEV | LKRKVIEKVQ |

200:

HIQLLQKNVR | AQLVDMKRLE | VDIDIKIRSC | RGSCSRALAR | EVDLKDYEDQ |

250:

QKQLEQVIAK | DLLPSRDRQH | LPLIKMKPVP | DLVPGNFKSQ | LQKVPPEWKA |

300:

LTDMPQMRME | LERPGGNEIT | RGGSTSYGTG | SETESPRNPS | SAGSWNSGSS |

350:

GPGSTGNRNP | GSSGTGGTAT | WKPGSSGPGS | TGSWNSGSSG | TGSTGNQNPG |

400:

SPRPGSTGTW | NPGSSERGSA | GHWTSESSVS | GSTGQWHSES | GSFRPDSPGS |

450:

GNARPNNPDW | GTFEEVSGNV | SPGTRREYHT | EKLVTSKGDK | ELRTGKEKVT |

500:

SGSTTTTRRS | CSKTVTKTVI | GPDGHKEVTK | EVVTSEDGSD | CPEAMDLGTL |

550:

SGIGTLDGFR | HRHPDEAAFF | DTASTGKTFP | GFFSPMLGEF | VSETESRGSE |

600:

SGIFTNTKES | SSHHPGIAEF | PSRGKSSSYS | KQFTSSTSYN | RGDSTFESKS |

650:

YKMADEAGSE | ADHEGTHSTK | RGHAKSRPVR | DCDDVLQTHP | SGTQSGIFNI |

700:

KLPGSSKIFS | VYCDQETSLG | GWLLIQQRMD | GSLNFNRTWQ | DYKRGFGSLN |

750:

DEGEGEFWLG | NDYLHLLTQR | GSVLRVELED | WAGNEAYAEY | HFRVGSEAEG |

800:

YALQVSSYEG | TAGDALIEGS | VEEGAEYTSH | NNMQFSTFDR | DADQWEENCA |

850:

EVYGGGWWYN | NCQAANLNGI | YYPGGSYDPR | NNSPYEIENG | VVWVSFRGAD |

866:

YSLRAVRMKI | RPLVTQ

3D Structure:

N/A

Predicted Eptitope:

Please Sign in.

Vaild Sequence:

Please Sign in.

Related Databases

Pfam:

SMR:

MIM:

KEGG:

STRING:

9606.ENSP00000306361

UniGene:

String:

Uniprot:

FOR

ELISA Kit for Human Fibrinogen alpha chain

ELISA Kit for Human Fibrinogen alpha chain

ELISA Kit for Human Fibrinogen alpha chain

ELISA Kit for Human Fibrinogen alpha chain

ELISA Kit for Human Fibrinogen alpha chain

ELISA Kit for Human Fibrinogen alpha chain

ELISA Kit for Human Fibrinogen alpha chain

CLIA Kit for Human Fibrinogen alpha chain

CLIA Kit for Human Fibrinogen alpha chain

CLIA Kit for Human Fibrinogen alpha chain

CLIA Kit for Human Fibrinogen alpha chain

CLIA Kit for Human Fibrinogen alpha chain

CLIA Kit for Human Fibrinogen alpha chain

CLIA Kit for Human Fibrinogen alpha chain

Polyclonal Antibody for Human Fibrinogen alpha chain

Polyclonal Antibody for Human Fibrinogen alpha chain

Polyclonal Antibody for Human Fibrinogen alpha chain

Polyclonal Antibody for Human Fibrinogen alpha chain

Polyclonal Antibody for Human Fibrinogen alpha chain

Polyclonal Antibody for Human Fibrinogen alpha chain

Polyclonal Antibody for Human Fibrinogen alpha chain

Monoclonal Antibody for Human Fibrinogen alpha chain

Monoclonal Antibody for Human Fibrinogen alpha chain

Monoclonal Antibody for Human Fibrinogen alpha chain

Monoclonal Antibody for Human Fibrinogen alpha chain

Monoclonal Antibody for Human Fibrinogen alpha chain

Monoclonal Antibody for Human Fibrinogen alpha chain

Monoclonal Antibody for Human Fibrinogen alpha chain

Protein for Human Fibrinogen alpha chain

Protein for Human Fibrinogen alpha chain

Protein for Human Fibrinogen alpha chain

Protein for Human Fibrinogen alpha chain

Protein for Human Fibrinogen alpha chain

Protein for Human Fibrinogen alpha chain

Protein for Human Fibrinogen alpha chain

R&D Technical Data

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

s

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

Precision

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

Intra-assay Precision (Precision within an assay):Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

Intra-Assay CV: ≤9.1%

Inter-assay Precision (Precision between assays):Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

Inter-Assay CV: ≤12.4%

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

Recovery

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

Recovery was determined by spiking various levels of FIBA into serum and plasma .

Sample Type	Average(%)	Recovery Range(%)
Serum	105	96-108
Plasma	104	100-106

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

Linearity

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of FIBA and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample	1：2	1:4	1:8	1:16
serum(n=5)	102-110%	104-112%	98-106%	96-106%
EDTA plasma(n=5)	103-108%	96-105%	98-107%	102-108%
heparin plasma(n=5)	95-110%	96-102%	101-106%	105-109%

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

Citations

[1].

"Circulation levels of acute phase proteins in patients with Takayasu arteritis"

J Ma, X Luo, Q Wu, et al.

From:JOURNAL OF VASCULAR SURGERY

[2].

"Identification of Novel Biomarkers in Seasonal Allergic Rhinitis by Combining Proteomic, Multivariate and Pathway Analysis"

H Wang, J Gottfries, F Barrenäs, et al.

[3].

"Cocktail Blood Biomarkers: Prediction of Clinical Outcomes in Patients with Acute Ischemic Stroke"

Zeng L. · Liu J. · Wang Y. · Wang L. · Weng S. · Chen S. · Yang G.-Y.

From:European Neurology

[4].

"Differences of Circulating Inflammatory Markers between Large- and Small Vessel Disease in Patients with Acute Ischemic Stroke"

L Zeng, X He, J Liu, et al.

From:International journal of medical sciences

[5].

"Plasma levels of thrombomodulin, plasminogen activator inhibitor-1 and fibrinogen in elderly, diabetic patients with depressive symptoms"

Gorska-Ciebiada M, Saryusz-Wolska M, Borkowska A, et al.

From:Aging clinical and experimental research

References

1.

"Localization of the alpha-chain cross-link acceptor sites of human fibrin."
Fretto L.J. , Ferguson E.W. , Steinman H.M. , McKee P.A.
J. Biol. Chem.253:2184-2195(1978) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: CROSS-LINKING ACCEPTOR SITES
2.

"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry."
Liu T. , Qian W.-J. , Gritsenko M.A. , Camp D.G. II , Monroe M.E. , Moore R.J. , Smith R.D.
J. Proteome Res.4:2070-2080(2005) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-686
tissue: Plasma.
3.

"Disulfide bridges in NH2-terminal part of human fibrinogen."
Blombaeck B. , Hessel B. , Hogg D.
Thromb. Res.8:639-658(1976) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: DISULFIDE BONDS
4.

"Fibrinogen and fibrin."
Doolittle R.F.
Annu. Rev. Biochem.53:195-229(1984) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: REVIEW;ELECTRON MICROSCOPY;POLYMERIZATION;LIGANDS
5.

"Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor."
Kimura S. , Aoki N.
J. Biol. Chem.261:15591-15595(1986) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: CROSS-LINKING SITE FOR ALPHA-2-PLASMIN INHIBITOR
6.

"Phosphorylation of fibrinogen by casein kinase 1."
Itarte E. , Plana M. , Guasch M.D. , Martos C.
Biochem. Biophys. Res. Commun.117:631-636(1983) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PHOSPHORYLATION
7.

"Phosphoproteomic analysis of the human pituitary."
Beranova-Giorgianni S. , Zhao Y. , Desiderio D.M. , Giorgianni F.
Pituitary9:109-120(2006) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-22;IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
tissue: Pituitary.
8.

"Phosphoproteome of resting human platelets."
Zahedi R.P. , Lewandrowski U. , Wiesner J. , Wortelkamp S. , Moebius J. , Schuetz C. , Walter U. , Gambaryan S. , Sickmann A.
J. Proteome Res.7:526-534(2008) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-412 AND SER-609;IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
tissue: Platelet.
9.

"Prolyl 4-hydroxylation of alpha-fibrinogen: a novel protein modification revealed by plasma proteomics."
Ono M. , Matsubara J. , Honda K. , Sakuma T. , Hashiguchi T. , Nose H. , Nakamori S. , Okusaka T. , Kosuge T. , Sata N. , Nagai H. , Ioka T. , Tanaka S. , Tsuchida A. , Aoki T. , Shimahara M. , Yasunami Y. , Itoi T. , more...
J. Biol. Chem.284:29041-29049(2009) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: HYDROXYLATION AT PRO-565
10.

"Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry."
Chen R. , Jiang X. , Sun D. , Han G. , Wang F. , Ye M. , Wang L. , Zou H.
J. Proteome Res.8:651-661(2009) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-686
tissue: Liver.
11.

"A unique proteolytic fragment of human fibrinogen containing the A alpha COOH-terminal domain of the native molecule."
Kirschbaum N.E. , Budzynski A.Z.
J. Biol. Chem.265:13669-13676(1990) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: CLEAVAGE BY HEMENTIN AND PLASMIN
12.

"Initial characterization of the human central proteome."
Burkard T.R. , Planyavsky M. , Kaupe I. , Breitwieser F.P. , Buerckstuemmer T. , Bennett K.L. , Superti-Furga G. , Colinge J.
BMC Syst. Biol.5:17-17(2011) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
13.

"Glycoproteomic analysis of human fibrinogen reveals novel regions of O-glycosylation."
Zauner G. , Hoffmann M. , Rapp E. , Koeleman C.A. , Dragan I. , Deelder A.M. , Wuhrer M. , Hensbergen P.J.
J. Proteome Res.11:5804-5814(2012) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: GLYCOSYLATION AT THR-320 AND SER-351
14.

"Characterization of fibrinogen glycosylation and its importance for serum/plasma N-glycome analysis."
Adamczyk B. , Struwe W.B. , Ercan A. , Nigrovic P.A. , Rudd P.M.
J. Proteome Res.12:444-454(2013) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: LACK OF GLYCOSYLATION
15.

"The structure of residues 7-16 of the A alpha-chain of human fibrinogen bound to bovine thrombin at 2.3-A resolution."
Martin P.D. , Robertson W. , Turk D. , Huber R. , Bode W. , Edwards B.F.P.
J. Biol. Chem.267:7911-7920(1992) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 26-39
16.

"Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin."
Spraggon G. , Everse S.J. , Doolittle R.F.
Nature389:455-462(1997) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 130-216
17.

"Carboxy-terminal-extended variant of the human fibrinogen alpha subunit: a novel exon conferring marked homology to beta and gamma subunits."
Fu Y. , Weissbach L. , Plant P.W. , Oddoux C. , Cao Y. , Liang T.J. , Roy S.N. , Redman C.M. , Grieninger G.
Biochemistry31:11968-11972(1992) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA];ALTERNATIVE SPLICING (ISOFORMS 1 AND 2)
18.

"Fibrinogen DNA and protein sequences."
Chung D.W. , Grieninger G.

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE (ISOFORM 1)
19.

SeattleSNPs variation discovery resource
Submitted (2001-06) to the EMBL/GenBank/DDBJ databases

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA];VARIANTS VAL-6; ALA-331 AND ALA-456
20.

"Complete sequencing and characterization of 21,243 full-length human cDNAs."
Ota T. , Suzuki Y. , Nishikawa T. , Otsuki T. , Sugiyama T. , Irie R. , Wakamatsu A. , Hayashi K. , Sato H. , Nagai K. , Kimura K. , Makita H. , Sekine M. , Obayashi M. , Nishi T. , Shibahara T. , Tanaka T. , Ishii S. , more...
Nat. Genet.36:40-45(2004) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2);VARIANT ALA-331
tissue: Heart.
21.

Mural R.J. , Istrail S. , Sutton G.G. , Florea L. , Halpern A.L. , Mobarry C.M. , Lippert R. , Walenz B. , Shatkay H. , Dew I. , Miller J.R. , Flanigan M.J. , Edwards N.J. , Bolanos R. , Fasulo D. , Halldorsson B.V. , Hannenhalli S. , Turner R. , more...
Submitted (2005-09) to the EMBL/GenBank/DDBJ databases

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
22.

"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
The MGC Project Team
Genome Res.14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2)
23.

"Nucleotide sequences of the three genes coding for human fibrinogen."
Chung D.W. , Harris J.E. , Davie E.W.
Adv. Exp. Med. Biol.281:39-48(1990) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE OF 1-655 (ISOFORM 1)
tissue: Liver.
24.

"Partial mRNA sequences for human A alpha, B beta, and gamma fibrinogen chains: evolutionary and functional implications."
Kant J.A. , Lord S.T. , Crabtree G.R.
Proc. Natl. Acad. Sci. U.S.A.80:3953-3957(1983) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2)
25.

"Characterization of a complementary deoxyribonucleic acid coding for the alpha chain of human fibrinogen."
Rixon M.W. , Chan W.-Y. , Davie E.W. , Chung D.W.
Biochemistry22:3237-3244(1983) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 1-629
26.

"Human fibrinogen: sequence, sulfur bridges, glycosylation and some structural variants."
Henschen A. , Lottspeich F. , Southan C. , Topfer-Petersen E.

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PROTEIN SEQUENCE OF 20-629
27.

"Amino acid sequence studies on the alpha chain of human fibrinogen. Overlapping sequences providing the complete sequence."
Watt K.W.K. , Cottrell B.A. , Strong D.D. , Doolittle R.F.
Biochemistry18:5410-5416(1979) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PROTEIN SEQUENCE OF 20-629;DISULFIDE BONDS
28.

"Isolation and characterisation of cDNA clones for the A alpha- and gamma-chains of human fibrinogen."
Imam A.M.A. , Eaton M.A.W. , Williamson R. , Humphries S.
Nucleic Acids Res.11:7427-7434(1983) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 110-156
29.

"Cloning of fibrinogen genes and their cDNA."
Chung D.W. , Rixon M.W. , Que B.G. , Davie E.W.
Ann. N. Y. Acad. Sci.408:449-456(1983) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE OF 605-644 (ISOFORM 2)
30.

"Studies on fibrinopeptides from primates."
Blombaeck B. , Blombaeck M. , Grondahl N.J. , Guthrie C. , Hinton M.
Acta Chem. Scand.19:1788-1789(1965)

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PROTEIN SEQUENCE OF 20-35
31.

"Amino acid sequence studies on the alpha chain of human fibrinogen. Exact location of cross-linking acceptor sites."
Cottrell B.A. , Strong D.D. , Watt K.W.K. , Doolittle R.F.
Biochemistry18:5405-5410(1979) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: CROSS-LINKING ACCEPTOR SITES
32.

"Crystal structure of fragment double-D from human fibrin with two different bound ligands."
Everse S.J. , Spraggon G. , Veerapandian L. , Riley M. , Doolittle R.F.
Biochemistry37:8637-8642(1998) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 130-216
33.

"Crystal structure of a recombinant alphaEC domain from human fibrinogen-420."
Spraggon G. , Applegate D. , Everse S.J. , Zhang J.Z. , Veerapandian L. , Redman C. , Doolittle R.F. , Grieninger G.
Proc. Natl. Acad. Sci. U.S.A.95:9099-9104(1998) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 666-866;GLYCOSYLATION AT ASN-686
34.

"Conformational changes in fragments D and double-D from human fibrin(ogen) upon binding the peptide ligand Gly-His-Arg-Pro-amide."
Everse S.J. , Spraggon G. , Veerapandian L. , Doolittle R.F.
Biochemistry38:2941-2946(1999) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 130-216
35.

"Fibrinogen Kyoto II, a new congenitally abnormal molecule, characterized by the replacement of A alpha proline-18 by leucine."
Yoshida N. , Okuma M. , Hirata H. , Matsuda M. , Yamazumi K. , Asakura S.
Blood78:149-153(1991) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT KYOTO-2 LEU-37
36.

"Fibrinogen Lima: a homozygous dysfibrinogen with an A alpha-arginine-141 to serine substitution associated with extra N-glycosylation at A alpha-asparagine-139. Impaired fibrin gel formation but normal fibrin-facilitated plasminogen activation catalyzed by tissue-type plasminogen activator."
Maekawa H. , Yamazumi K. , Muramatsu S. , Kaneko M. , Hirata H. , Takahashi N. , Arocha-Pinango C.L. , Rodriguez S. , Nagy H. , Perez-Requejo J.L. , Matsuda M.
J. Clin. Invest.90:67-76(1992) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT LIMA SER-160
37.

"An A alpha Ser-434 to N-glycosylated Asn substitution in a dysfibrinogen, fibrinogen Caracas II, characterized by impaired fibrin gel formation."
Maekawa H. , Yamazumi K. , Muramatsu S. , Kaneko M. , Hirata H. , Takahashi N. , de Bosch N.B. , Carvajal Z. , Ojeda A. , Arocha-Pinango C.L. , Matsuda M.
J. Biol. Chem.266:11575-11581(1991) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT CARACAS-2 ASN-453
38.

"Molecular basis for fibrinogen Dusart (A alpha 554 Arg-->Cys) and its association with abnormal fibrin polymerization and thrombophilia."
Koopman J. , Haverkate F. , Grimbergen J. , Lord S.T. , Mosesson M.W. , Diorio J.P. , Siebenlist K.S. , Legrand C. , Soria J. , Soria C. , Caen J.P.
J. Clin. Invest.91:1637-1643(1993) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT DUSART/PARIS-5 CYS-573
39.

"Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain."
Benson M.D. , Liepnieks J. , Uemichi T. , Wheeler G. , Correa R.
Nat. Genet.3:252-255(1993) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT AMYL8 LEU-573
40.

"Fibrinogen Osaka IV: a congenital dysfibrinogenemia found in a patient originally reported in relation to surgery, now defined to have an A alpha arginine-16 to histidine substitution."
Yamazumi K. , Terukina S. , Matsuda M. , Kanbayashi J. , Sakon M. , Tsujinaka T.
Surg. Today23:45-50(1993) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT OSAKA IV HIS-35
41.

"Aberrant hepatic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (A-alpha 20 Val-to-Asp)."
Brennan S.O. , Hammonds B. , George P.M.
J. Clin. Invest.96:2854-2858(1995) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT CANTERBURY ASP-39
42.

"Characterization of single-nucleotide polymorphisms in coding regions of human genes."
Cargill M. , Altshuler D. , Ireland J. , Sklar P. , Ardlie K. , Patil N. , Shaw N. , Lane C.R. , Lim E.P. , Kalyanaraman N. , Nemesh J. , Ziaugra L. , Friedland L. , Rolfe A. , Warrington J. , Lipshutz R. , Daley G.Q. , Lander E.S.
Nat. Genet.22:231-238(1999) [PubMed] [Europe PMC] [Abstract]

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS ALA-331 AND GLU-446
43.

Cargill M. , Altshuler D. , Ireland J. , Sklar P. , Ardlie K. , Patil N. , Shaw N. , Lane C.R. , Lim E.P. , Kalyanaraman N. , Nemesh J. , Ziaugra L. , Friedland L. , Rolfe A. , Warrington J. , Lipshutz R. , Daley G.Q. , Lander E.S.
Nat. Genet.23:373-373(1999)

[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: ERRATUM

Product Feedback Wall

Hot Genes: Atf2 ASPRO ACE ALCAM C19orf80 Trap1a Gdf5

Top Searches: Ubiquitin-protein ligase metalloproteinase Ubiquitin ELISA Tumor necrosis Alpha Asprosin TRAP1A

Why choose EIAAB: Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more

Further Information: About us Protein center Bank account Distributors Terms & Conditions Career eiaab.com.cn

Copyright & copy www.eiaab.com2006-2016 All Rights Reserved EIAab Email:eiaab@eiaab.com

鄂ICP备10015095号-1

鄂公网安备 42018502005535号